^
    Back
    Association details:
    Biomarker:ALK positive
    Cancer:Non-Hodgkin’s Lymphoma
    Drug:Anboni (unecritinib) (ALK inhibitor, ROS1 inhibitor, c-MET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)

    Excerpt:
    ...3.Histologically or cytologically confirmed ALK positive relapsed or refractory Anaplastic Large Cell Lymphoma....
    Trial ID:
    TQ-B3101-II-02
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2022
    Title:

    2940 Phase I Study of Tq-B3101 in Pediatric Patients with Relapsed/Refractory Anaplastic Lymphoma Kinase Positive Anaplastic Large Cell Lymphoma

    Published date:
    11/03/2022
    Excerpt:
    The ORR was 100%, with four patients achieving complete response (CR) and three patients achieving a partial response (PR)….Our preliminary results suggest that TQ-B3101 has significant clinical activity in children with R/R ALK+ ALCL. Responses were durable and ongoing, and treatment was well tolerated.
    DOI:
    https://doi.org/10.1182/blood-2022-164661
    Trial ID:
    TQ-B3101-II-02